Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Email this article to a friend

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

Vanna Chiarion-Sileni*, Paola Del Bianco, Antonella Romanini, Michele Guida, Adriano Paccagnella, Maurizio Dalla Palma, Emanuele Naglieri, Ruggero Ridolfi, Barbara Silvestri, Maria Michiara and Gian Luca De Salvo

BMC Cancer 2006, 6:44  doi:10.1186/1471-2407-6-44

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive BMC Cancer's emails?